Journal of Innovations in Pharmaceutical and Biological Sciences
Read the article
Visual summary · Journal of Innovations in Pharmaceutical and Biological Sciences

Computational Elucidation of the Antidiabetic Mechanism of Catechin and Apigenin via Network Pharmacology and Molecular Docking

Shaikh Faizan, Shaikh Asif Ayyub, Shaikh Mehmood Dawood

The question

How might apigenin and catechin act against type 2 diabetes, and at which targets?

  • Type 2 Diabetes Mellitus (T2DM) is a lasting metabolic disease marked by insulin resistance, poor control of glucose, oxidative stress, inflammation and failing beta cells in the pancreas.
  • Its rising incidence, and the drawbacks of the usual antidiabetic treatments, make safer agents from natural products that act on several targets worth looking for.
  • Apigenin and catechin are described as anti-inflammatory and antioxidant, able to lower blood sugar and make the body more sensitive to insulin.

What was done

Twocompounds studied: apigenin and catechin
Publicdatabases for genes and compound targets
Metforminthe comparison in the docking work
  • The study examined how the two compounds might work against type 2 diabetes, joining network pharmacology to molecular docking.
  • Genes tied to the disease, and the likely targets of the two compounds, were sought in databases open to the public.
  • Protein-protein interaction, Gene Ontology and KEGG pathway enrichment work followed.

Key findings

Finding 1 of 4
Hub genes
tied to insulin signalling and the handling of glucose, among them AKT1

Network analysis found important hub genes bearing on insulin signalling and the handling of glucose, among them PIK3R1 and ESR1, AKT1 and EGFR, and PTK2.

Finding 2 of 4
PI3K-Akt
and the endocrine resistance pathway were significantly enriched

By the KEGG analysis, the PI3K-Akt pathway and the endocrine resistance pathway were significantly enriched.

Finding 3 of 4
-6.4 kcal/mol
catechin's binding affinity at AKT1

Catechin bound strongly, at -6.1 kcal/mol to PIK3R1 and at -6.4 kcal/mol to AKT1.

Finding 4 of 4
Apigenin
scored -5.7 kcal/mol at PIK3R1 and -6.3 kcal/mol at AKT1

Apigenin's docking scores at those same two genes were -5.7 kcal/mol and -6.3 kcal/mol, set beside Metformin.

Why it matters

  • The authors say the results give a scientific foundation for further experimental confirmation, and imply that the two compounds may have antidiabetic effects by acting at several targets.
  • The work joined network pharmacology to molecular docking, on genes and targets taken from public databases.

How to cite

Shaikh Faizan, Shaikh Asif Ayyub, Shaikh Mehmood Dawood. Computational Elucidation of the Antidiabetic Mechanism of Catechin and Apigenin via Network Pharmacology and Molecular Docking. Journal of Innovations in Pharmaceutical and Biological Sciences. 2026;13(01):03-13. https://doi.org/10.56511/jipbs.2026.13102

Open the article